ASX Share rice
Fri 14 May 2021 - 07:26:pm (Sydney)

CAN Share Price

CANN GROUP LIMITEDCANPharmaceuticals, Biotechnology & Life Sciences

CAN Company Information

Name:

Cann Group Limited

Sector:

Healthcare

Industry:

Drug Manufacturers-Specialty & Generic

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

Walter & Eliza Hall Inst. of Medical Res Bundoora VIC Australia 3083

Phone:

61 3 9095 7088

Chief Exec. Officer:

Mr. Peter Crock M.B.A., MBA

Chief Financial Officer:

Mr. Greg Bullock

Chief Operating Officer:

Mr. Shane Duncan

Chief Projects & Information Officer:

Mr. Geoff Aldred

Chief Compliance Officer & Company Sec.:

Ms. Geraldine T. Farrell B.Sc., FCIS, L.L.B., L.L.M.

Head of Investor Relations:

Mr. Clive Fanning

Head of Legal:

Mr. Steven Notaro

Company Overview:

Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.

CAN Share Price Information

Shares Issued:

277.84M

Market Capitalisation:

$113.92M

Revenue (TTM):

$6.23M

Revenue Per Share (TTM):

$0.04

Earnings per Share:

$-0.078

Profit Margin:

-2.8811

Operating Margin (TTM):

$-2.16

Return On Assets (TTM):

$-0.09

Return On Equity (TTM):

$-0.21

Quarterly Revenue Growth (YOY):

8.13

Gross Profit(TTM):

$0.96M

Diluted Earnings Per Share (TTM):

$-0.108

CAN CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-34,362,408

Change To Liabilities:

$1.19M

Total Cashflow From Investing Activities:

$-34,362,408

Net Borrowings:

$7.59M

Net Income:

$-16,937,387

Total Cash From Operating Activities:

$-17,618,574

Depreciation:

$2.16M

Change To Inventory:

$-6,563,931

Change To Account Receivables:

$1.02M

Sale Purchase Of Stock:

$8M

Capital Expenditures:

$33.12M

CAN Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-16,937,390

Net Income:

$-16,937,390

Gross Profit:

$6.52K

Operating Income:

$-16,346,170

Interest Expense:

$869.03K

Total Revenue:

$647.22K

Cost Of Revenue:

$640.70K

CAN Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$827.64K

Total Liabilities:

$15.33M

Total Stockholder Equity:

$61.07M

Total Assets:

$76.40M

Common Stock:

$97.14M

Other Current Assets:

$609.86K

Retained Earnings:

$-38,205,379

Other Assets:

$85K

Cash:

$1.55M

Total Current Liabilities:

$6.49M

Property - Plant & Equipment:

$61.95M

Net Tangible Assets:

$60.25M

Long-Term Investments:

$1.01M

Total Current Assets:

$12.53M

Long-Term Debt:

$8.19M

Net Receivables:

$91.64K

Short-Term Investments:

$63.87M

Inventory:

$9.43M

Accounts Payable:

$6M

Non Currrent Assets (Other):

$85K

Short-Term Investments:

$63.87

Non Current Liabilities Total:

$8.84M

CAN Share Price History

CAN News

23 Feb, 2021
We feel now is a pretty good time to analyse Cann Group Limited's ( ASX:CAN ) business as it appears the company may be...
16 Feb, 2021
Satipharm sale reinforces Harvest One's strategic realignment and transition to become a cannabis-focused Consumer Packaged Goods ("CPG") companyHarvest One has the opportunity to continue to represent Satipharm-branded products in North AmericaVancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Harvest One Cannabis Inc. (TSXV: HVT) (OTCQB: HRVOF) ("Harvest One" or the "Company"), a uniquely positioned, cannabis-infused CPG leader, announced today that it has entered into a definitive sale agreement (the "Agreement") to sell all ...
25 Nov, 2020
One thing we could say about the covering analyst on Cann Group Limited (ASX:CAN) - they aren't optimistic, having...
14 Oct, 2020
Aurora Cannabis Inc. (NYSE: ACB) opted to part ways with Australia-based Cann Group.The Canadian cannabis company sold its 12% stake via off-market trades "to a small number of undisclosed buyers" on Friday, Oct 9, after the market closed.Aurora is also selling its assets in Uruguay, per MJ Biz Daily. Alejandro Antalich, the CEO overseeing the company's South American operations, exited the company, the report continued.Both developments come on the heels of Aurora's fourth-quarter earnings report, which was released Monday.During the last fiscal year, the company lost over CA$3.3 billion ($2.5 billion).In addition, its impairment loss amounted to CA$37.2 million ($28.2 million) on its Cann Group position for the fiscal year. In the last year, the impairment charge was CA$18.2 million.Aurora spokeswoman Michelle Lefler told the cannabis business news outlet that they "continue to see growth potential in this important market and will maintain active relationships with key distribution partners to enhance the availability of Aurora's portfolio of leading, high-quality medical cannabis."As a part of its "business transformation plan," executive chair Michael Singer recently noted that the company has been "building the infrastructure and capabilities necessary for a successful and diversified business."Singer was appointed to the role after serving as the company's interim CEO for over six months.Lefler further explained that Aurora's primary focus is on its "core markets," including the medical and recreational market in Canada, the development of international medical markets, and the CBD market in the U.S. on which the company debuted in May.Courtesy imageSee more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Cannabis Movers & Shakers: Aurora, One World Pharma * Aurora Cannabis Touts 'Business Transformation Plan,' Confirms New CEO And Financial Update(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
07 Jul, 2020
Cann Group Limited (ASX:CAN) shareholders might be concerned after seeing the share price drop 15% in the last month...